A detailed history of Td Waterhouse Canada Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Td Waterhouse Canada Inc. holds 30 shares of ALNY stock, worth $7,139. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30
Previous 836 96.41%
Holding current value
$7,139
Previous $203 Million 95.94%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$233.81 - $287.01 $188,450 - $231,330
-806 Reduced 96.41%
30 $8.26 Million
Q2 2024

Nov 12, 2024

SELL
$143.31 - $247.0 $1,003 - $1,729
-7 Reduced 0.83%
836 $203 Million
Q2 2024

Aug 02, 2024

SELL
$143.31 - $247.0 $286 - $494
-2 Reduced 0.24%
843 $173 Million
Q1 2024

May 10, 2024

BUY
$146.51 - $198.2 $4,541 - $6,144
31 Added 3.81%
845 $131 Million
Q4 2023

Feb 12, 2024

SELL
$151.41 - $196.57 $3,936 - $5,110
-26 Reduced 3.1%
814 $159 Million
Q3 2023

Nov 13, 2023

SELL
$170.77 - $211.65 $8,538 - $10,582
-50 Reduced 5.62%
840 $154 Million
Q2 2023

Nov 13, 2023

SELL
$185.01 - $212.05 $7,585 - $8,694
-41 Reduced 4.4%
890 $172 Million
Q1 2023

Nov 13, 2023

SELL
$182.66 - $235.53 $730 - $942
-4 Reduced 0.43%
931 $191 Million
Q4 2022

Nov 13, 2023

SELL
$185.53 - $241.31 $36,920 - $48,020
-199 Reduced 17.55%
935 $223 Million
Q3 2022

Nov 13, 2023

SELL
$138.54 - $232.0 $232,470 - $389,296
-1,678 Reduced 59.67%
1,134 $227 Million
Q2 2022

Nov 13, 2023

SELL
$120.42 - $169.29 $4,214 - $5,925
-35 Reduced 1.23%
2,812 $422 Million
Q1 2022

Nov 13, 2023

SELL
$127.18 - $173.91 $3,688 - $5,043
-29 Reduced 1.01%
2,847 $489 Million
Q4 2021

Nov 13, 2023

BUY
$159.56 - $209.29 $458,894 - $601,918
2,876 New
2,876 $482 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Td Waterhouse Canada Inc. Portfolio

Follow Td Waterhouse Canada Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Waterhouse Canada Inc., based on Form 13F filings with the SEC.

News

Stay updated on Td Waterhouse Canada Inc. with notifications on news.